$BBIO * BRIDGEBIO PHARMA TC FIB EWP DAILY TF ANALYSISThe chart is suggesting that NASDAQ:BBIO is in the process of a Wave 4 correction, which should push the price lower in the short term. The correction appears to be reaching support levels near $18 or $17, which could be a good area for a reversal.
If the correction holds these levels, the next m
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.26 EUR
−517.53 M EUR
214.35 M EUR
155.25 M
About BridgeBio Pharma, Inc.
Sector
Industry
CEO
Neil Kumar
Website
Headquarters
Palo Alto
Founded
2015
FIGI
BBG01TNWLS59
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
BBIO – A Promising Stock & Buy OpportunityNASDAQ:BBIO has been performing very well since May of 2022, and has recently been in a downtrend. BBIO lost support at the light blue support line, and more recently had a bullish rebound off the yellow support line. I think BBIO is likely to present more buy opportunities around $27.15, and this
bbio daily buy/hold setup 200% gains strong chart🔸Hello guys, let's review the daily price chart for BBIO today. Noteworthy compression in
progress, and also a decent sequence of higher lows, therefore expecting more gains in BBIO.
Short-term pullback into May/June, however should find support near 10 usd later. Currently
trading at 15.85 usd. Ope
BridgeBio Making bridges to bigger broker accounts. BBIO Yes, another pharma stock in the green. Let's go, baby!
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
BBIO5355568
BridgeBio Pharma, Inc. 2.25% 01-FEB-2029Yield to maturity
5.05%
Maturity date
Feb 1, 2029
US10806XAH5
BRIDGEBIO PH 25/31CV 144AYield to maturity
0.06%
Maturity date
Mar 1, 2031
BBIO5151039
BridgeBio Pharma, Inc. 2.5% 15-MAR-2027Yield to maturity
−6.73%
Maturity date
Mar 15, 2027
See all 1BBIO bonds
Related stocks
Frequently Asked Questions
The current price of 1BBIO is 33.96 EUR — it has increased by 0.029% in the past 24 hours. Watch BRIDGEBIO PHARMA INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange BRIDGEBIO PHARMA INC stocks are traded under the ticker 1BBIO.
1BBIO stock has risen by 7.23% compared to the previous week, the month change is a 7.23% rise, over the last year BRIDGEBIO PHARMA INC has showed a 7.23% increase.
We've gathered analysts' opinions on BRIDGEBIO PHARMA INC future price: according to them, 1BBIO price has a max estimate of 84.17 EUR and a min estimate of 32.78 EUR. Watch 1BBIO chart and read a more detailed BRIDGEBIO PHARMA INC stock forecast: see what analysts think of BRIDGEBIO PHARMA INC and suggest that you do with its stocks.
1BBIO stock is 0.029% volatile and has beta coefficient of 1.04. Track BRIDGEBIO PHARMA INC stock price on the chart and check out the list of the most volatile stocks — is BRIDGEBIO PHARMA INC there?
Yes, you can track BRIDGEBIO PHARMA INC financials in yearly and quarterly reports right on TradingView.
BRIDGEBIO PHARMA INC is going to release the next earnings report on Jul 31, 2025. Keep track of upcoming events with our Earnings Calendar.
1BBIO earnings for the last quarter are −0.81 EUR per share, whereas the estimation was −0.85 EUR resulting in a 4.13% surprise. The estimated earnings for the next quarter are −0.70 EUR per share. See more details about BRIDGEBIO PHARMA INC earnings.
BRIDGEBIO PHARMA INC revenue for the last quarter amounts to 107.81 M EUR, despite the estimated figure of 55.61 M EUR. In the next quarter, revenue is expected to reach 78.66 M EUR.
1BBIO net income for the last quarter is −154.76 M EUR, while the quarter before that showed −256.03 M EUR of net income which accounts for 39.56% change. Track more BRIDGEBIO PHARMA INC financial stats to get the full picture.
No, 1BBIO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 4, 2025, the company has 730 employees. See our rating of the largest employees — is BRIDGEBIO PHARMA INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BRIDGEBIO PHARMA INC EBITDA is −627.77 M EUR, and current EBITDA margin is −257.45%. See more stats in BRIDGEBIO PHARMA INC financial statements.
Like other stocks, 1BBIO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BRIDGEBIO PHARMA INC stock right from TradingView charts — choose your broker and connect to your account.